Genotoxic evaluation of ornidazole and secnidazole in albino mice: an experimental study

Shreenivas P. Revankar, Vedavathi H.


Background: The present study was planned to explore the genotoxic potential of some commonly used antimicrobials like ornidazole and secnidazole in swiss albino mice.

Methods: Therapeutic equivalent doses of ornidazole and secnidazole were given by intra peritoneal route. Single dose in individual groups of mice (n=5 in each) was administered for acute study. Doses were repeated every 24 hrs for 7 times in additional groups of mice (n=5 in each) for sub-acute study. Cyclophosphamide served as positive control while normal saline as negative control. After 24 hrs of single dose (acute study) and last dose of drug administration in sub-acute study, about 0.5 ml of blood was collected by retro orbital sinus for comet assay as described earlier (Rojas E et al, 1999) and later the mice were sacrificed to aspirate the femoral bone marrow for micronucleus test as described earlier by described by Schmid W (1975). In comet assay, the total comet length and head diameter was measured under microscope using ocular & stage micrometer to calculate comet tail length. In micronucleus assay, the stained bone marrow tissue smears were scored for the frequency of micronucleated polychromatic erythrocytes (MnPCE) and also the ratio between polychromatic erythrocytes (PCE) to normochromic erythrocytes (NCE) was obtained.

Results: It was analyzed by one-way ANOVA followed by Dunnet’s multiple comparison tests. Significant (P< 0.01) increase in comet tail length and percentage of micronucleated polychromatic erythrocytes (% MnPCE) was observed in groups treated with single and multiple doses of Cyclophosphamide whereas ornidazole and secnidazole treated groups did not show any significant changes.

Conclusions: The results indicate that Ornidazole and secnidazole are devoid of genotoxicity.



Ornidazole, Secnidazole, Cyclophosphamide, Comet assay, Micronucleus assay, Genotoxicity

Full Text:



Jena GB, Kaul CL, Rama RP. Genotoxicity testing, a regulatory requirement for drug discovery and development: Impact of ICH guidelines. Indian Journal of Pharmacology. 2002;34:86-9.

Schmid W. The micronucleus test. Mutation research. 1975;31:9-15.

E. Rojas, M.C. Lopez, M. Valverde, Single cell gel electrophoresis assay: methodology and applications, Journal of Chromatography. 1999;B722:225–54.

Fenech M. Biomarkers of genetic damage for cancer epidemiology. Toxicology. 2002;181-182:411-6.

G. Krishna, Hayashi M. In vivo rodent micronucleus assay: Protocol, conduct and data interpretation. Mutation research. 2000;455:155-66.

Dobias L, Cerna M, Rossner P, Sram R. Genotoxicity and carcinogenicity of metronidazole. Mutat Res. 1994Jun;317(3):177-94.

Bendesky A, Menendez D, Ostrosky-Wegman P. Is metronidazole carcinogenic? Mutat Res. 2002 Jun;511(2):133-44.

Voogd CE, Van der Stel JJ, Jacobs JJ. The mutagenic action of nitroimidazoles. II. Tinidazole, ipronidazole, panidazole and ornidazole. Mutat Res. 1977 Apr;48(2):155-61.

Rang HP, Dale MM, Ritter JM, Moore PK. Pharmacology. 5th ed. Edinburg: Churchill Livingstone; 2003.

Hardman JG, Limbard LE. Goodman & Gilman’s The Pharmacological Basis of Therapeutics.10th Ed. New York: McGraw-Hill Medical publishing division; 2001.

Hundal BS, Dhillon VS, Sidhu IS. Genotoxic potential of estrogens. Mutation Research. 1997;389:173–81.

Sawant SG, Kozlowski RS, Couch DB. The role of adrenal corticosteroids in induction of micronuclei. Mutation Research. 2001;498:129-33.

Menendez D, Bendesky A, Rojas E, Salamanca F, Ostrosky-Wegman P. Role of P53 functionality in the genotoxicity of metronidazole and its hydroxy metabolite. Mutat Res. 2002Apr25;501(1-2):57-67.

Hrelia P, Murelli L, Paolini M, Cantelli-Forti G. In vivo protective role of antioxidants against genotoxicity of metronidazole and azanidazole. Drugs Exp Clin Res. 1987;13(9):577-83.

Cantelli-Forti G, Aicardi G, Guerra MC, Barbaro AM, Biagi GL. Mutagenicity of a series of 25 nitroimidazoles and two nitrothiazoles in Salmonella typhimurium. Teratog Carcinog Mutagen. 1983;3(1):51-63

Gómez-Arroyo S, Melchor-Castro S, Villalobos-Pietrini R, Camargo EM, Salgado-Zamora H, Campos Aldrete ME. Cytogenetic study of metronidazole and three metronidazole analogues in cultured human lymphocytes with and without metabolic activation. Mutat Res. 2004Jun;18(3):319-24.

Carballo MA, Palermo AM, Mudry MD. Toxicogenetic evaluation of metronidazole in the treatment of women infected with Trichomonas vaginalis Mutat Res. 2004Mar;98(2):139-47.

S.B. Nadin, L.M. Vargas-Roig, D.R. Ciocca, A silver staining method for single-cell Gel assay, The journal of histochemistry and cytochemistry. 2001;49:1183-6.

Fahrig R, Engelke M. Reinvestigation of in vivo genotoxicity studies in man. I. No induction of DNA strand breaks in peripheral lymphocytes after metronidazole therapy. Mutat Res. 1997 Dec12;395(2-3):215-21.